Clinical, humanistic, and economic outcomes of gout

American Journal of Managed Care

Volumn 11, Issue SUPPL. 15, 2005, Pages

  Brixner, Diana I ^a   Ho, Mei Jen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL TOXICITY; GOUT; HEALTH CARE COST; HUMAN; MANAGED CARE ORGANIZATION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; CAUSALITY; COST OF ILLNESS; DISEASE MANAGEMENT; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH BEHAVIOR; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; WORLD HEALTH;

EID: 28344448569     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders United States. Arthritis Rheum. 1998;41:778-799.
2. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004;31:1575-1581.
3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-426.
4. Gutman AB. The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum. 1973;16:431-445.
5. O'Duffy JD, Hunder GG, Kelly PJ. Decreasing prevalence of tophaceous gout. Mayo Clin Proc. 1975;50:227-228.
6. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582-1587.
7. Ho G Jr, Denuccio M. Gout and pseudogout in hospitalized patients. Arch Intern Med. 1993;153:2787-2790.
8. Roberts C, Adebajo AO, Long S. Improving the quality of care of musculoskeletal conditions in primary care. Rheumatology (Oxford). 2002;41:503-508.
9. Reginato AJ, Schumacher HR Jr. Crystal-associated arthropathies. Clin Geriatr Med. 1988;4:295-322.
10. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch Intern Med. 2005;165:742-748.
11. Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract. 2003;20:413-416.
12. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539-543.
13. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-1281.
14. Choi HK, Curhan G. Gout: epidemiology and life-style choices. Curr Opin Rheumatol. 2005;17:341-345.
15. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician. 1999;59:925-934.
16. Agarwal AK. Gout and pseudogout. Prim Care. 1993;20:839-855.
17. Hawkins DW, Rahn DW. Gout and hyperuricemia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 3rd ed. Stamford, Conn: Appleton & Lange; 1997:1755-1761.
18. Barrett K, Miller ML, Wilson JT. Tophaceous gout of the spine mimicking epidural infection: case report and review of the literature. Neurosurgery. 2001;48:1170-1172.
19. Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. J Rheumatol. 2003;30:2437-2443.
20. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22:908-914.
21. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002;59:245-250.
22. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30:44-54.
23. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-325.
24. Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther. 2003;25:1593-1617.
25. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am. 1990;16:539-550.
26. Joish VN, Donaldson G, Stockdale W, et al. The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin. 2005;21:535-544.
27. Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards. Ann Intern Med. 1997;127:52-60.
28. Hurley JS, Frost EJ, Trinkaus KM, Buatti MC, Emmett KE. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. Am J Manag Care. 1998;4:1691-1698.
29. Liang MH, Phillips E, Scamman M. Design and evaluation of a pilot community program for musculoskeletal disability. J Community Health. 1981;6:257-266.
30. Nicol KK, Ward WC, Pike EJ, Geisinger KR, Cappellari JO, Kilpatrick SE. Fine-needle aspiration biopsy of gouty tophi: lessons in cost-effective patient management. Diagn Cytopathol. 1997;17:30-35.